# Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside

> **NCT03383614** · PHASE1 · COMPLETED · sponsor: **Drugs for Neglected Diseases** · enrollment: 24 (actual)

## Conditions studied

- Filariasis

## Interventions

- **DRUG:** LSF emodepside (BAY 44-4400) or matching placebo

## Key facts

- **NCT ID:** NCT03383614
- **Lead sponsor:** Drugs for Neglected Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-14
- **Primary completion:** 2018-10-15
- **Final completion:** 2018-10-15
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-04-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03383614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03383614, "Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03383614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*